Liquid Biopsy Market: Current Analysis and Forecast (2021-2027)

Liquid Biopsy Market: Current Analysis and Forecast (2021-2027)

  • UnivDatos Market Insight
  • July 2021
  • Healthcare
  • 128 pages

Report Description

The growth of the liquid biopsy market is primarily driven by increasing prevalence of cancer, growing adoption of non-invasive diagnostic and monitoring techniques and increasing preference of personalized medicines. In addition, technological advancement, increasing government initiatives to develop healthcare infrastructure and large availability funding’s for research and development for liquid biopsy is likely to contribute to the growth of liquid biopsy market during the forecast period. 

In January 2020, Personal Genome Diagnostics Inc. partnered with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology.

Based on the type, the global Liquid Biopsy market is categorized into Lung, Breast, Colorectal, Prostate. Lung Cancer segment accounted for the largest revenue share in 2020 owning to increase in prevalence of non-small cell lung cancer form across the globe For instance, as per the world health organization, lung cancer is by far the leading cause of cancer death among both men and women, estimated to have around 1.80 millions death globally in 2020. Further, prostrate cancer is expected to be the fastest growing segment during the forecast period as it is the most prevalent type of cancer and the second leading cause of death in North America.

Based on Circulating Biomarker, the global Liquid Biopsy Market has been segmented into Circulating Tumour Cells (CTCs), Circulating Tumour DNA (CTDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVS), and others. Circulating Tumour Cells accounted for the largest market share in 2020, during the forecast period. Circulating Tumour DNA (ctDNA) was the second-largest market in 2020. Circulating Tumour cells (CTCs) are considered to have an encouraging perspective as a liquid biopsy that can simplify early detection, prognosis, therapeutic target selection, and monitoring therapeutic response. 

Based on product and service, the liquid biopsy market is segmented into assay kits, instruments, and services. Among these, the assay kits segment is expected to be the fastest-growing segment in the product and services market during the forecast period. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected.

Based on end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers. Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The can be attributed to the large volume of tests being outsourced to reference laboratories from oncologists and hospitals.

For a better understanding of the market penetration of the Liquid Biopsy  market, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia and Rest of APAC), and Rest of World. North America constitutes a major market for disposable medical device sensor and generated revenue of USD XX million in 2020 owing to the presence of well-established players in the region, emerging investment in healthcare R&D by players etc., However, the Asia Pacific region would grow at the highest CAGR during the forecast period.

Some of the major players operating in the Liquid Biopsy  market are Roche Diagnostics, Biocept, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Menarini-Silicon Biosystems, Illumina, Inc., MDXhealth SA, Genomic Health, Inc., Guardant Health Inc.

The global liquid biopsy market was valued at USD XX million in 2018 and is expected to reach USD XX million in 2026, growing at a CAGR of XX% during the forecast period. Liquid biopsy is a non-invasive procedure which enables doctors to identify the information regarding the tumor using a blood sample. This technique is mainly used to diagnose chronic diseases such as cancer. It is also used to monitor the effect of treatment on cancer patients’ multiple times. The liquid biopsy will take a prominent position for cancer-related probe and investigation. The liquid biopsy is rapidly substituting conventional tumor biopsies. These are developed out of the need to acquire the most amount of molecular information about cancer. This cancer information is obtained with the least amount of surgical invasion. Furthermore, the clinical trials for the development of these tests have given positive results and have led to larger scaled clinical trials demonstrating efficacy.

The global liquid biopsy market was valued at USD XX million in 2020 and is expected to reach USD XX million in 2027, growing at a CAGR of XX% during the forecast period. Liquid biopsy is a non-invasive procedure which enables doctors to identify the information regarding the tumor using a blood sample. This technique is mainly used to diagnose chronic diseases such as cancer. It is also used to monitor the effect of treatment on cancer patients’ multiple times. The liquid biopsy will take a prominent position for cancer-related probe and investigation. The liquid biopsy is rapidly substituting conventional tumor biopsies. These are developed out of the need to acquire the most amount of molecular information about cancer. This cancer information is obtained with the least amount of surgical invasion. Furthermore, the clinical trials for the development of these tests have given positive results and have led to larger scaled clinical trials demonstrating efficacy.

The incidence rates of cancer remain highest in the more-developed regions; however, the mortality is relatively higher in the less-developed countries due to limited access to treatment facilities and lack of awareness regarding the benefits of early detection. Lung cancer, colorectal cancer, breast cancer, and prostate cancer account for the majority of cancer cases. Lung cancer is the leading cause of death among all cancers. Similarly, breast cancer is the second-most common type of cancer globally and is also the most common cause of cancer-related deaths in women.

Liquid biopsy holds several benefits over traditional cancer diagnostics techniques—reduced cost, early prognosis, therapy monitoring, detection of tumor heterogeneity, acquired drug resistance, and patient comfort (by eliminating the need for surgery).

In April 2017, Menarini Silicon Biosystems (Italy), Inc. acquired Janssen Diagnostics, LLC. (US). This acquisition of Janssen Diagnostics' business related to CELLSEARCH Circulating Tumor Cell System. The acquisition marks Menarini-Silicon Biosystems’ first entry into the US diagnostics market.

The key players in the global liquid biopsy market are Roche Diagnostics, Biocept, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Menarini-Silicon Biosystems, Illumina, Inc., MDXhealth SA, Genomic Health, Inc., Guardant Health Inc. Several M&A’s along with partnerships have been undertaken by these players to develop new and advanced technologies.

Insights Presented in the Report

“Amongst Cancer Type, Lung Cancer segment holds the major share.”

Based on the cancer type, the global Liquid Biopsy market is categorized into Lung, Breast, Colorectal, Prostate. Lung Cancer segment accounted for the largest revenue share in 2020 owning to increase in prevalence of non-small cell lung cancer form across the globe.  For instance, as per the world health organization, lung cancer is by far the leading cause of cancer death among both men and women, estimated to have around 1.80 million deaths globally in 2020. Further, prostate cancer is expected to be the fastest growing segment during the forecast period as it is the most prevalent type of cancer and the second leading cause of death in North America. 

“Amongst Product, Assay Kits segment dominated the market during the forecast period.”

Based on product, the liquid biopsy market is segmented into assay kits, instruments. Among these, the assay kits segment is expected to be the fastest-growing segment in the product and services market during the forecast period. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected. 

“Amongst End User, Hospital’s segment dominated the market during the forecast period.”

Based on end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centres. Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. They can be attributed to the large volume of tests being outsourced to reference laboratories from oncologists and hospitals.

 “North America represents one of the largest markets of Liquid Biopsy market.”

For a better understanding of the market dynamics of the Liquid Biopsy market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of US$ XX million in 2020 owing to the rising per capita income. 

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts
  • The report presents a quick review of overall industry performance at one glance
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
  • The study comprehensively covers the market across different segments
  • Deep dive regional level analysis of the industry

Customization Options:

The Liquid Biopsy Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Companies Covered

  • Roche Diagnostics
  • Biocept, Inc.
  • Thermo Fisher Scientific Inc.
  • Qiagen N.V.
  • Bio-Rad Laboratories, Inc.
  • Menarini-Silicon Biosystems
  • Illumina, Inc.
  • MDXhealth SA
  • Genomic Health, Inc.
  • Guardant Health Inc.

Have query on this report?

Make an Enquiry

Table of Content

1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Objective of the Study
1.3. Limitation
1.4. Stake Holders
1.5. Currency Used in Report
1.6. Scope of the Global Liquid Biopsy Market Study

2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Methodology for the Global Liquid Biopsy Market
2.1.1. Main Objective of the Global Liquid Biopsy Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 GLOBAL LIQUID BIOPSY MARKET REVENUE

7 MARKET INSIGHTS BY TYPE

7.1. Lung
7.2. Breast
7.3. Colorectal
7.4. Prostate

8 MARKET INSIGHTS BY CIRCULATING BIOMARKERS
8.1. Circulating Tumor Cells
8.2. Circulating Tumor DNA
8.3. Cell-Free DNA

9 MARKET INSIGHTS BY PRODUCT
9.1. Instruments
9.2. Assay Kits

10 MARKET INSIGHTS BY END USER
10.1. Reference Laboratories
10.2. Hospitals and Physician Laboratories
10.3. Academic and Research Centers

11 MARKET INSIGHTS BY REGION
11.1. North America Liquid Biopsy Market
11.1.1. United States
11.1.2. Canada
11.1.3. Rest of North America
11.2. Europe Liquid Biopsy Market
11.2.1. Germany
11.2.2. France
11.2.3. U.K.
11.2.4. Spain
11.2.5. Italy
11.2.6. Rest of Europe
11.3. Asia Pacific Liquid Biopsy Market
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. Rest of Asia Pacific
11.4. Rest of the World Liquid Biopsy Market

12 LIQUID BIOPSY MARKET DYNAMICS
12.1. Market Drivers
12.2. Market Challenges
12.3. Impact Analysis

13 LEGAL & REGULATORY FRAMEWORK

14 DEMAND AND SUPPLY SIDE ANALYSIS

14.1. Demand Side Analysis
14.2. Supply Side Analysis
14.2.1. Top Product Launches
14.2.2. Top Business Partnerships
14.2.3. Top Merger & Acquisitions

15 VALUE CHAIN ANALYSIS

16 LIQUID BIOPSY MARKET OPPORTUNITIES

17 LIQUID BIOPSY MARKET TRENDS & INSIGHTS

18 COMPETITIVE SCENARIO

18.1. Porter’s Five forces analysis
18.1.1. Bargaining power of Supplier
18.1.2. Bargaining power of Buyer
18.1.3. Industry Rivalry
18.1.4. Availability of Substitute
18.1.5. Threat of new Entrants

19 COMPANY PROFILED
19.1. Thermo Fisher Scientific, Inc.
19.1.1. Key Facts
19.1.2. Business Description
19.1.3. Key Product/Services Offerings
19.1.4. Growth Strategy
19.1.5. SWOT Analysis
19.1.6. Key Financials
19.1.6.1. Revenue Split
19.1.6.2. Financial Overview of Thermo Fisher Scientific, Inc.
19.1.7. Recent Developments
19.1.7.1. Product Launch
19.1.7.2. Partnerships
19.1.7.3. Business Expansion and Investments
19.1.7.4. Merger and Acquisition
19.2. Roche Diagnostics
19.3. Biocept, Inc
19.4. Thermo Fisher Scientific Inc
19.5. Qiagen N.V.
19.6. Bio-Rad Laboratories, Inc
19.7. Menarini-Silicon Biosystems
19.8. Illumina, Inc
19.9. MDXhealth SA
19.10. Genomic Health, Inc

20 DISCLAIMER

Success Stories

Our Clients